FDA declines to grant accelerated approval for Eli Lilly’s experimental Alzheimer’s treatment

Fda Declines To Grant Accelerated Approval For Eli Lilly’s Experimental Alzheimer’s Treatment

FDA has declined to grant accelerated approval to an experimental Alzheimer’s drug, donanemab, and requested additional data from Eli Lilly and Company, the drug maker.